{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:34:55Z","timestamp":1776850495616,"version":"3.51.2"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dev Pharmacol Ther"],"abstract":"<jats:p>Zinc deuteroporphyrin IX 2,4-bis-glycol (ZnBG) is a potent inhibitor of heme\noxygenase and may be useful in the prevention of neonatal jaundice. Enteral administration\ncould be advantageous clinically, but it has been only minimally effective with other metalloporphyrins\nin rats and humans. Thus, the absorption of ZnBG by the small intestine in\nvivo was examined. ZnBG was administered enterally at 40 \u03bcmol\/kg to 2-week-old suckling\nrats via in situ catheterization of the small intestine. Within 15 min ZnBG was absorbed by\nthe small intestine, as it was measured in portal and systemic venous plasma, intestine,\nkidney, liver, and spleen. Concentrations exceeding 5.0 \u03bcM were found in plasma within\n30 min, and 9.4 \u03bcM was found in the liver after 30 min. A total of 4.6% of the administered\nZnBG dose was measured in plasma and tissues.<\/jats:p>","DOI":"10.1159\/000457506","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T17:08:31Z","timestamp":1502471311000},"page":"109-115","source":"Crossref","is-referenced-by-count":10,"title":["Absorption of Zinc Deuteroporphyrin IX 2,4-Bis-GIycol by the\nNeonatal Rat Small Intestine in vivo"],"prefix":"10.1159","author":[{"given":"Heather A.","family":"Vallier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela A.","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo O.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David K.","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,8,11]]},"container-title":["Developmental Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000457506","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:34:41Z","timestamp":1776846881000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000457506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000457506","archive":["Portico"],"relation":{},"ISSN":["0379-8305","2504-2505"],"issn-type":[{"value":"0379-8305","type":"print"},{"value":"2504-2505","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}